EC approves ThromboGenics' ocriplasmin

ThromboGenics N.V. (Euronext:THR) said the European Commission approved an MAA for Jetrea ocriplasmin to treat vitreomacular traction, including when associated with a macular hole of 400 um or less in diameter. The approval triggered a EUR 45 million ($58.5 million) milestone payment to ThromboGenics from the Alcon Inc. ophthalmic unit of Novartis AG (NYSE:NVS; SIX:NOVN). Last March, ThromboGenics granted Alcon ex-U.S. commercialization rights to the injectable recombinant microplasmin, a truncated form of the natural human protein plasmin (see BioCentury Extra, March 16, 2012). ...